M. Takeda

Anti‐factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation

M. Shima, A. Yoshioka, T. Igawa, 2014, Journal of thrombosis and haemostasis : JTH.

Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.

K. Nogami, M. Shima, T. Igawa, 2014, Blood.

Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance

Yuichiro Yamada, Y. Kawabe, T. Kitazawa, 2015, Journal of diabetes research.

Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice

T. Fukuzawa, Takamitsu Kobayashi, Y. Kawabe, 2012, Journal of Pharmacology and Experimental Therapeutics.

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models

T. Fukuzawa, Y. Kawabe, Kiyofumi Honda, 2014, Nutrition & Diabetes.

Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.

M. Shima, A. Yoshioka, T. Igawa, 2014, Journal of thrombosis and haemostasis : JTH.

Tofogliflozin, a novel sodium–glucose co‐transporter 2 inhibitor, improves renal and pancreatic function in db/db mice

T. Fukuzawa, T. Mori, Y. Kawabe, 2013, British journal of pharmacology.